Viracta Therapeutics, Inc.
A pharmaceutical company working on developing drugs to treat virus-related malignancies. The company is developing orally administered drugs to treat Epstein-Barr virus (EBV)-related lymphomas and solid cancers. The company's approach is to target the EBV genome and induce the expression of a specific viral kinase gene, thereby activating antiviral drugs to kill tumor cells. Based in Delaware
Overview
Overview | |
|---|---|
Country | United States |
State | California |
Employees | 40 |
Founded | 2007 |
Financials | |
|---|---|
Market Capitalization | 21.13M |
Revenue | |
Operating Income | -52.36M |
Operating Margin | |
Net Income | -47.99M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4481 / 5373 |
Sector : Healthcare | 730 / 1144 |
Industry : Biotechnology | 331 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 4936 / 5565 |
Sector : Healthcare | 947 / 1182 |
Industry : Biotechnology | 527 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4327 / 5436 |
Sector : Healthcare | 705 / 1164 |
Industry : Biotechnology | 336 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4540 / 5330 |
Sector : Healthcare | 846 / 1174 |
Industry : Biotechnology | 406 / 667 |